Amgen’s multiple myeloma drug Kyprolis received approval for a label expansion from the U.S. Food and Drug Administration, including results from a trial that showed a longer survival rate and 21 percent reduced risk of death. The results from the ASIRE trial, which studied Kyprolis in combination with lenalidomide and dexamethasone, were published in the…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
